Understanding Enlarged Prostate
Benign prostatic hyperplasia (BPH), commonly known as enlarged prostate, affects more than 50 percent of men over 50 and up to 90 percent of those over 80. This non-cancerous condition involves the prostate gland, walnut-sized organ below the bladder, growing and compressing the urethra. Symptoms include lower urinary tract symptoms (LUTS) such as frequent urination, urgency, weak urine stream, incomplete emptying, and nocturia, disrupting daily life and sleep. Untreated BPH can lead to complications like urinary tract infections, bladder stones, or acute urinary retention. Traditional treatments range from medications like alpha-blockers and 5-alpha reductase inhibitors to surgeries such as transurethral resection of the prostate (TURP). However, emerging therapies like Aquablation offer precise, minimally invasive alternatives for symptom relief.
What is Aquablation Therapy
Aquablation therapy represents a robotic, image-guided procedure using high-velocity, pressurized waterjets to remove excess prostate tissue. FDA-approved in 2017, it employs the AquaBeam Robotic System, combining ultrasound imaging for real-time prostate mapping with automated waterjet ablation. Unlike laser or electrocautery methods, Aquablation avoids thermal energy, reducing risks to surrounding tissues. The procedure typically lasts 30-60 minutes under general or spinal anesthesia, suitable for prostates of any size, including those over 150 grams where other options falter.
How Aquablation Works
During Aquablation, a surgeon inserts a transurethral scope into the urethra. Ultrasound provides a 3D map of the prostate, allowing personalized treatment planning to preserve key structures like the ejaculatory ducts and verumontanum. The robotic arm then delivers a precise waterjet—shaped like a shield—to ablate only enlarged tissue while sparing healthy areas. Heat-free ablation minimizes bleeding, with hemostasis achieved via a balloon catheter. Patients often go home the next day with a catheter for 1-2 days, experiencing rapid symptom improvement.
Benefits and Advantages
Clinical trials, including the WATER study, demonstrate Aquablation’s superiority in preserving sexual function compared to TURP, with 90 percent anejaculation-free rates versus 35 percent. It offers durable IPSS score reductions (International Prostate Symptom Score) by over 16 points at five years, low reintervention rates under 2 percent, and consistent outcomes regardless of prostate size or surgeon experience. Recovery is swift, with most resuming normal activities within weeks, and it excels for large glands where open prostatectomy was once standard.
Potential Risks and Considerations
While safe, Aquablation carries risks like temporary hematuria, urinary incontinence (resolving in 94 percent), or ejaculatory dysfunction (rare). Contraindications include active urinary infections or prostate cancer. Costs are higher initially, but reduced complications may offset long-term expenses. Consultation with a urologist is essential to assess candidacy based on prostate volume, symptoms, and health status.
Conclusion
Aquablation therapy transforms BPH management, providing precise, tissue-preserving treatment with excellent functional outcomes. As awareness grows, it empowers men with enlarged prostates to reclaim urinary health and quality of life. Ongoing research continues to affirm its role in urology, bridging innovation and reliability for sustainable relief.